TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01570010

Intervention type: OTHER
Group type: OTHER
Intervention: Norwegian food based dietary guidelines
Description: several means will be applied to guide participarts to cohere to the dietary guidelines including access to clinical nutritionists, free food, food discounts, cooking courses, cookbook/recipies, study website, organized physical activity, etc

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Norwegian food based dietary guidelines
Description: several means will be applied to guide participarts to cohere to the dietary guidelines including access to clinical nutritionists, free food, food discounts, cooking courses, cookbook/recipies, study website, organized physical activity, etc
Study: NCT02797561

Intervention type: OTHER
Intervention: 5 year Follow-up
Study: NCT02088034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotora-led Intervention
Description: Behavioral life-style program lead by a team of trained community health workers (called promotoras) with 2 principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Therapy
Description: Participants in this group will receive metformin 850 mg bid for one year.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in this arm will attend one physician visit to discuss healthy lifestyle behaviors and will receive standard educational materials.
Study: NCT00661765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline tartrate
Description: Single dose of 2.0 mg oral Chantix (varenicline) immediate release tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline free base
Description: A single 2.0 mg dose of varenicline transdermal delivery system applied to the skin for a 24 hour period.
Study: NCT00792766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus (RAD001)
Description: Subjects will resume the dosing regimen that they were receiving at the completion of the initial RAD001 study.
Study: NCT00768378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with the BrainPort balance device
Description: Subjects are randomly assigned to one of two groups, the perceived stimulation group or the subliminal stimulation group. Some of these devices provide a stimulus that you can feel. Others provide a stimulus that is below conscious awareness. We are conducting this study to determine if one type of stimulation is more effective than the other.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with the BrainPort balance device
Description: Subjects are randomly assigned to one of two groups, the perceived stimulation group or the subliminal stimulation group. Some of these devices provide a stimulus that you can feel. Others provide a stimulus that is below conscious awareness. We are conducting this study to determine if one type of stimulation is more effective than the other.
Study: NCT01720771

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic tablet
Description: Intake of one probiotic lozenge tablet per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: one tablet daily
Study: NCT02704429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRN1008
Description: Part A dosing was initiated administering 400 mg BID. Intrapatient dose adjustments (reductions and increases) were permitted based upon tolerability and clinical response with the maximum dose allowed up to 600 mg BID for 12 weeks.~Part B initial dosing was 400 mg QD for 2 weeks with dose escalation to 400 mg BID at the discretion of the Investigator for the purposes of investigating dose response and identifying the minimal efficacious dose of rilzabrutinib for 24 weeks.
Study: NCT04283877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 3 x 10 mg oral tablets. Single acute dose for all participants

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 3 x 10 mg oral lactose tablet for all participants
Study: NCT01380093

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single-dose, 2 x microcrystalline cellulose (weighed to equal weights of average tablet/capsule of active comparator) mixed with 150 ml artificially sweetened, non-carbonated beverage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MS Contin (morphine sulfate, controlled release)
Description: Single-dose, 2 x 60 mg morphine sulfate whole tablets manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMBEDA (morphine sulfate / naltrexone hydrochloride)
Description: Single-dose, solution 2 x 60 mg morphine sulfate with sequestered 2.4 mg Naltrexone hydrochloride whole capsules manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
Study: NCT00091793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 162
Description: 60 mg/mL denosumab given day 1, month 6, month 12 and month 18

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given at day 1, month 6, month 12 and month 18
Study: NCT03952650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine Phosphate
Description: Chloroquine phosphate is approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a blood-stage schizonticide, highly active against replicating forms of blood-stage drug- sensitive parasites. As such, it is routinely employed as first-line prophylaxis against development of patent parasitemia and clinical malaria in non-immune travelers to areas with chloroquine sensitive Pf. In the pilot, chloroquine administration will begin with a loading dose 2 days prior to PfSPZ Challenge and finishing with a maintenance dose 5 days after PfSPZ Challenge. In the main phase, chloroquine will be first administered as a loading dose 2 days prior to PfSPZ Challenge and continuing weekly using a maintenance dose for a total of 10 doses, finishing with a last dose 5 days after the third injection with PfSPZ Challenge.
Study: NCT02057835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 691751
Description: Placebo to BI 691751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 691751
Description: Placebo to BI 691751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751 low dose 2
Description: BI 691751 low dose 2
Study: NCT04889014

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Personal genomic educational testing (PGET)
Description: PGET consisted of a panel of pharmacogenomic variants

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: No personal genomic educational testing (NPGET)
Description: Lack of pharmacogenomic testing
Study: NCT03528187

Intervention type: OTHER
Intervention: MRI
Description: MRI scan (not involving ionising radiation)~The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher

Intervention type: OTHER
Intervention: MRI
Description: MRI scan (not involving ionising radiation)~The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher

Intervention type: OTHER
Intervention: MRI
Description: MRI scan (not involving ionising radiation)~The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher

Intervention type: OTHER
Intervention: Written Consent
Description: Student researcher or research nurses to take consent. Consent will be taken in the obesity clinic or radiology departments.

Intervention type: OTHER
Intervention: Written Consent
Description: Student researcher or research nurses to take consent. Consent will be taken in the obesity clinic or radiology departments.

Intervention type: OTHER
Intervention: Written Consent
Description: Student researcher or research nurses to take consent. Consent will be taken in the obesity clinic or radiology departments.
Study: NCT03556618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Person Care (WPC) Reentry Program - Pre & Post Release services
Description: Social network intervention to provide care coordination and social support during youth reentry before release and post-release from jail.
Study: NCT03952650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine Phosphate
Description: Chloroquine phosphate is approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a blood-stage schizonticide, highly active against replicating forms of blood-stage drug- sensitive parasites. As such, it is routinely employed as first-line prophylaxis against development of patent parasitemia and clinical malaria in non-immune travelers to areas with chloroquine sensitive Pf. In the pilot, chloroquine administration will begin with a loading dose 2 days prior to PfSPZ Challenge and finishing with a maintenance dose 5 days after PfSPZ Challenge. In the main phase, chloroquine will be first administered as a loading dose 2 days prior to PfSPZ Challenge and continuing weekly using a maintenance dose for a total of 10 doses, finishing with a last dose 5 days after the third injection with PfSPZ Challenge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chloroquine Phosphate
Description: Chloroquine phosphate is approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a blood-stage schizonticide, highly active against replicating forms of blood-stage drug- sensitive parasites. As such, it is routinely employed as first-line prophylaxis against development of patent parasitemia and clinical malaria in non-immune travelers to areas with chloroquine sensitive Pf. In the pilot, chloroquine administration will begin with a loading dose 2 days prior to PfSPZ Challenge and finishing with a maintenance dose 5 days after PfSPZ Challenge. In the main phase, chloroquine will be first administered as a loading dose 2 days prior to PfSPZ Challenge and continuing weekly using a maintenance dose for a total of 10 doses, finishing with a last dose 5 days after the third injection with PfSPZ Challenge.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: PfSPZ Challenge (NF54) acts as the immunogen in the PfSPZ-CVac approach to vaccinating against malaria. Participants will receive either one (in the pilot phase) or 3 (in the main phase) 400,000 or 300,000 aseptic, purified, cryopreserved, fully infectious PfSPZ injections by DVI (with concurrent administration of antimalarial drugs). Following immunization, participants in the main phase will be followed through the transmission season in order to assess vaccine efficacy.
Study: NCT00912444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide
Description: Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 every 3 weeks for six cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, cyclophosphamide
Description: Docetaxel 75mg/m2, cyclophosphamide 600mg/m2 every 3 weeks for six cycles
Study: NCT00416949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-specific dosimetry
Description: Patient-specific 3D-RD dosimetry was applied to the data collected
Study: NCT01011296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: Single 0.2mg dose of intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: Single 1mg dose of intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: Single 3 mg dose of intravenous infusion
Study: NCT00038415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLL vaccine using DNA plasmid vector
Study: NCT02117154

Intervention type: DEVICE
Intervention: 6-day Continuous Glucose Monitoring System
Description: performed 3 times on a patient, one month apart
Study: NCT04574505

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eufortyn Colesterolo Plus
Description: Food supplement combination containing bergamot (Vazguard®) phytosomal polyphenolic fraction associated with standardized artichoke extract (Pycrinil®, Cynara Cardunculus L) and Cynara scolimus, associated with high coenzyme Q10 bioavailability(Q10 phytosome® Ubiqsome) and zinc.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02015936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Six Week Physical Activity Intervention
Description: Tailored Wii Fit prescription based on physical fitness assessments and a schedule of six home visits by an oncology RN.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progress Reporting
Description: Participants will keep a log to record the physical activities they have done with the Wii Fit during the 6-week period. Audio-recording may be included for quality control. Self-report data will be collected by Internet surveys through the University of South Florida (USF) Health Qualtrics application at baseline (T1) and at 6 weeks post-intervention (T2). The nurse will take small amount of the participant's hair (20 strands) for a hormone test during the first visit and last visit.
Study: NCT06737263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioHPP abutment
Description: Patients in the test group receive abutments made of BioHPP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium abutment
Description: Patients in the control group receive abutments made of titanium

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zirconia abutment
Description: Patients in the control group receive abutments made of zirconia
Study: NCT00875459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIAject™
Description: Subcutaneous injection 25 IU/mL
Study: NCT00406237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigecycline
Description: Single intravenous dose of tigecycline 50 mg, as a 30-minute infusion
Study: NCT03281720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAD
Description: the same intervention as listed in the arm description
Study: NCT03514537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microcannula harvest adipose stromal tissues
Description: Use of disposable, closed syringe microcannula harvest autologous adipose stroma and stem/stromal cells

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centricyte 1000
Description: Centricyte 1000, closed system digestion of stromal vascular fraction to isolate and concentrate stem/stromal cells associated with microvasculature

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sterile Normal Saline IV Deployment of cSVF
Description: Sterile Normal Saline Suspension cSVF in 500 cc for Intravenous Delivery including 150 micron in-line filtration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liberase
Description: Liberase TM for use to enzymatically isolate cellular stromal vascular fraction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Sterile, Normal Saline 500 for Intravenous use
Study: NCT03555344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mantra Chikitsa
Description: Specific Mantra were given to chants for 15 mins and resting in the impact of chants for following 15 mins.
Study: NCT04405388

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo will be given orally as capsule (same size and weight as Spermidine capula)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo will be given orally as capsule (same size and weight as Spermidine capula)

Intervention type: DRUG
Group type: OTHER
Intervention: Spermidine
Description: Spermidine will be given orally as capsule (4mg/day)

Intervention type: DRUG
Group type: OTHER
Intervention: Spermidine
Description: Spermidine will be given orally as capsule (4mg/day)
Study: NCT01178411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Tivantinib 360 mg (3 x 120 mg tablets or capsules) twice daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Cancer Combination Therapy
Description: Tivantinib 360 mg twice daily in combination with other anti-cancer therapy (eg, erlotinib,sorafenib, pemetrexed, docataxel, gemcitabine, irinotecan, and/or cetuximab) at the same dose and schedule in which they were administered in the original (previous) study.
Study: NCT04981561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-251
Description: Single dose of GATE-251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-251
Description: Single dose of GATE-251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-251
Description: Single dose of GATE-251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-251
Description: Single dose of GATE-251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-251
Description: Single dose of GATE-251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-251
Description: Single dose of GATE-251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-251
Description: Single dose of GATE-251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-251
Description: Single dose of GATE-251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-251
Description: Single dose of GATE-251

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05017636

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shock wave therapy
Description: The participants received the treatment protocol established by the manufacturer of the Thork Shock Wave® device, IBRAMED- Industria Brasileira de Equipamentos Electromédicos, Amparo, São Paulo approved by Anvisa No. 10360310036. (Figure 1). The parameters were, 4,000 thousand shots with energy of 180mJ and frequency of 15Hz with 15mm stainless steel tip and 2,000 shots with energy of 100mJ and frequency of 15Hz with 15mm plastic tip, and for the tip slip, Neutral Thork® Lotion, RMC was used. Seven ESWT sessions were held, the average time of each was seven minutes, twice a week and the seventh session was held minutes before the surgical procedure of bariatric surgery, therapy was performed in an area of 150cm² on the left side of the abdominal region following the midline. The right side of the participants' abdomen did not receive ESWT and was termed as control.
Study: NCT02887586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auricular needling
Description: Patients will be treated with auricular needling for 4 weeks. 4-8 specific auricular acupoints are selected unilaterally at a time, and alternate to another side every 2-3 days, treatment will last for 4 consecutive weeks. The following 4 ear acupoints points will be selected for every patient: Ear Shenmen, Stoma, Spleen, and Subcortex. Other ear acupoints including Triple Energizer, Liver, Sympathetic Nerve and Smallintestine will be selected based on the condition of patients. Treatment will be performed by a registered Chinese medicine practitioner.
Study: NCT03952650

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pyrimethamine
Description: Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia.~Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses or a total of 6 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pyrimethamine
Description: Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia.~Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses or a total of 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia.~Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses or a total of 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia.~Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses or a total of 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia.~Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses or a total of 6 doses.
Study: NCT04256031

Intervention type: OTHER
Intervention: Assessment
Description: The structured questionnaire, Visual Analogue Scale, Copenhagen Neck Functional Disability Scale, Shoulder Disability Questionnaire, World Health Organization Quality of Life Instrument-Short Form, and Smartphone Addiction Scale-Short Version will be applied to all participants respectively. Lastly, posture analysis will be performed to all participants by using the New York Posture Rating Chart.

Intervention type: OTHER
Intervention: Assessment
Description: The structured questionnaire, Visual Analogue Scale, Copenhagen Neck Functional Disability Scale, Shoulder Disability Questionnaire, World Health Organization Quality of Life Instrument-Short Form, and Smartphone Addiction Scale-Short Version will be applied to all participants respectively. Lastly, posture analysis will be performed to all participants by using the New York Posture Rating Chart.